Key Market Indicator:
In this news category you will find information from and about companies, organizations, institutions, products of all kinds and in a broad spectrum. To get a quick overview of current trends and developments, it's worth visiting daily.
DE000A2P4LJ5
Thu, 21.07.2022
PharmaSGP Holding SE
PharmaSGP successfully secures financing of up to € 160 million
Gräfelfing, 21 July 2022 – Following strong organic growth and the successful acquisition and integration of the four OTC brands Baldriparan®, Formigran®, Spalt® and Kamol® formerly owned by the GlaxoSmithKline Group (GSK) in the second half of 2021, PharmaSGP Holding SE achieved r [ … ]
Wed, 15.06.2022
PharmaSGP Holding SE
PharmaSGP Holding SE successfully holds 2022 AGM
- 91.07% of share capital represented
- Shareholders approve proposed dividend payment; all other agenda items approved by a clear majority
- Following record revenue in 2021, Management Board reports on growth prospects based on PharmaSGP platform
Gräfelfing, 15 June 2022 – PharmaSGP Holding SE [ … ]
Tue, 17.05.2022
PharmaSGP Holding SE
PharmaSGP: Another revenue record – Q1 2022 revenues up 67% year-on-year
Gräfelfing, 17 May 2022 – In the first quarter of 2022, German OTC pharmaceutical company PharmaSGP Holding SE continued its dynamic growth path of the previous quarters and achieved another revenue record of € 20.6 million on the basis of preliminary, unaudited results. [ … ]
Mon, 25.04.2022
PharmaSGP Holding SE
PharmaSGP expects to see clear double-digit revenue and profit growth in 2022
Gräfelfing, 25 April 2022 - After another record year, German pharmaceutical company PharmaSGP is targeting revenues of between 78 and 82 million euro for financial year 2022, up from 65.3 million euro in the year before, equating to planned growth of at least 19.5%. [ … ]
Mon, 04.04.2022
PharmaSGP Holding SE
PharmaSGP - Dividend at the upper end of the announced bandwidth after a record year in 2021
Gräfelfing, 04 April 2022 - At the end of February German OTC pharmaceuticals company PharmaSGP Holding SE (WKN: A2P4LJ) announced that the company had recorded a revenue record of € 65.3 million in financial year 2021 and adjusted earnings before inter [ … ]
Tue, 15.03.2022
PharmaSGP Holding SE
PharmaSGP achieves record results in 2021 - Adjusted EBITDA in Q4 up fivefold year-on-year
Gräfelfing, 15 March 2022 - Based on preliminary and as yet unaudited results, German OTC pharmaceutical company PharmaSGP Holding SE achieved revenues of € 65.3 million in 2021, representing a record in the company's history. The adjusted earnings before [ … ]
Thu, 17.02.2022
PharmaSGP Holding SE
PharmaSGP achieves record revenues in 2021 and exceeds analysts' expectations
Gräfelfing, 17 February 2022 - German OTC pharmaceutical company PharmaSGP achieved revenues of around € 65 million in the financial year 2021, reaching the upper end of the published guidance (€ 60 million to € 65 million). With the highest revenue in its company histor [ … ]
Tue, 16.11.2021
PharmaSGP Holding SE
PharmaSGP reporting 34% revenue growth and increased profitability in Q3 2021
Recorded at € 19.7 million, group revenue in Q3 2021 is around 34% above the previous year and around 40% above Q2 2021, both representing significant increases
Strong revenue development largely driven by organic growth in the existing portfolio
Integration of the acqu [ … ]
Thu, 16.09.2021
PharmaSGP Holding SE
PharmaSGP: Product portfolio further expanded and internationalisation driven forward in H1 2021
Group revenues (€ 26.4 million) and adjusted EBITDA (€ 6.5 million) impacted by an overall market burdened by Covid-19
Visible improvement in Q2 despite continued difficult market environment; market recovery expected in H2
Acquisition of Baldriparan( [ … ]
Tue, 31.08.2021
PharmaSGP Holding SE
PharmaSGP Group completes acquisition of OTC brand portfolio (Baldriparan(R), Formigran(R), Spalt(R) and Kamol(R)) from GSK
Gräfelfing, August 31, 2021 - PharmaSGP Holding SE announces the formal completion of the purchase agreement signed mid of June with GlaxoSmithKline Group on the acquisition of an OTC portfolio comprising the brands Baldripar [ … ]